Clinical Trial: Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization
Brief Summary:
- Purpose:Our animal study demonstrated the effectiveness of subconjunctival injection of bevacizumab in the inhibition of corneal neovasculization formation. The purpose of this human interventional study is to report the treatment outcome of subconjunctival injection of bevacizumab in patients with corneal neovascularization.
- Material and methods: We enrolled 13 patients with unilateral or bilateral clinically significant corneal neovascularization during Aug. 2007 to Jan. 2008. Subconjunctival injection of bevacizumab once per month for at most 7 times was performed according to clinical response.
- Main outcome measurements: resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity.
Detailed Summary:
Sponsor: National Taiwan University Hospital
Current Primary Outcome: Resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity [ Time Frame: prospective ]
Original Primary Outcome: Same as current
Current Secondary Outcome: major side effects [ Time Frame: prospective ]
Original Secondary Outcome: Same as current
Information By: National Taiwan University Hospital
Dates:
Date Received: May 19, 2008
Date Started: August 2007
Date Completion:
Last Updated: May 20, 2008
Last Verified: August 2007
